Integer Holdings Announces Conversion of Senior Notes
Integer Holdings Corporation (NYSE: ITGR) has recently made headlines with the announcement that its 2.125% Convertible Senior Notes, due in 2028, are now eligible for conversion. This pivotal move allows holders to convert their notes into either cash, common stock, or a combination of both. The option to convert is available from the beginning of this year until March 31, 2025, coinciding with a surge in the company's stock performance.
Details of the Convertible Notes
The conversion rate for these notes is set at 11.4681 shares per $1,000 of principal, placing the conversion price at approximately $87.20 per share. The recent performance of Integer’s stock has exceeded 130% of the conversion price, which is the gateway for holders to take advantage of this opportunity. As of now, Integer Holdings’ shares are trading close to their 52-week high at approximately $142.75, demonstrating appealing value for shareholders.
The Mechanics of Conversion
Note holders interested in this conversion can do so through The Depository Trust Company, or they may reach out to the conversion agent, Wilmington Trust, National Association, for detailed instructions on the process. It’s important to note that the decision to convert remains solely with the note holders.
Industry Presence and Performance
Integer Holdings is a key player in the medical device industry, offering innovative products and solutions to enhance patient care worldwide. The organization operates under various brands, including Greatbatch Medical and Lake Region Medical. Maintaining strong financial health is evident, with an impressive current ratio of 3.28 highlighting robust liquidity.
Recent Financial Developments
In light of recent adjustments in its financial model, Integer Holdings is witnessing positive shifts. Following the divestiture of its Electrochem division, analysts from Oppenheimer and Truist Securities have altered their price targets. Oppenheimer increased its target from $135.00 to $138.00, while Truist Securities revised its estimate from $147.00 to $163.00. Both firms continue to hold a positive outlook on the stock, projecting a favorable trajectory for future growth.
Future Outlook
With an eye on the future, Integer Holdings has updated its full-year 2024 forecast. The company now anticipates revenues to be between $1,707 million and $1,727 million, signaling a healthy growth of approximately 10% to 11%. Furthermore, the adjusted EBITDA for the year is projected to lie between $358 million and $368 million, marking a year-over-year rise of 18% to 21%.
Segment-specific Growth Projections
Particularly promising is the expectation of accelerated organic growth in Q4, especially within the Cardio & Vascular and Neuromodulation segments. These key areas are expected to contribute significantly to Integer’s encouraging financial outlook and continued success within the medical device market.
Frequently Asked Questions
What are the 2.125% Convertible Senior Notes?
These are debt securities issued by Integer Holdings that can be converted into cash, stock, or a combination based on the holder's choice.
When can these notes be converted?
The conversion period is from the beginning of this year until March 31, 2025.
How is the conversion price determined?
The conversion price has been set at approximately $87.20 per share, based on a conversion rate of 11.4681 shares per $1,000 of principal.
What has been the stock performance of Integer Holdings?
Integer Holdings’ stock recently reached close to its 52-week high price of around $142.75, showing strong market performance.
What is Integer Holdings’ future financial outlook?
The company anticipates revenues of $1,707 million to $1,727 million for 2024, with an expected growth in adjusted EBITDA, indicating positive financial health.
